DK200300222U3 - New polymorphic form of olanzapine designated Form IV. - Google Patents
New polymorphic form of olanzapine designated Form IV. Download PDFInfo
- Publication number
- DK200300222U3 DK200300222U3 DK200300222U DKBA200300222U DK200300222U3 DK 200300222 U3 DK200300222 U3 DK 200300222U3 DK 200300222 U DK200300222 U DK 200300222U DK BA200300222 U DKBA200300222 U DK BA200300222U DK 200300222 U3 DK200300222 U3 DK 200300222U3
- Authority
- DK
- Denmark
- Prior art keywords
- olanzapine
- distances
- polymorph
- diffraction pattern
- designated
- Prior art date
Links
- 229960005017 olanzapine Drugs 0.000 title description 30
- KVWDHTXUZHCGIO-UHFFFAOYSA-N olanzapine Chemical compound C1CN(C)CCN1C1=NC2=CC=CC=C2NC2=C1C=C(C)S2 KVWDHTXUZHCGIO-UHFFFAOYSA-N 0.000 title description 29
- 238000000634 powder X-ray diffraction Methods 0.000 description 7
- 238000002441 X-ray diffraction Methods 0.000 description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 229910016523 CuKa Inorganic materials 0.000 description 3
- 238000001157 Fourier transform infrared spectrum Methods 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 238000001556 precipitation Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 206010017943 Gastrointestinal conditions Diseases 0.000 description 1
- 208000028017 Psychotic disease Diseases 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Description
DK 2003 00222 WDK 2003 00222 W
DK 2003 00222 WDK 2003 00222 W
BRUGSMODELKRAVUTILITY MODEL REQUIREMENTS
1. Form IV olanzapinpolymorf med et typisk røntgenpulverdiffraktionsmønster repræsenteret ved følgende interplanare afstande: 5 d-afstand (Å) 9,9487 8,5074 8,2103 10 4,8172 4,7114 4,6122 4,5282 4,2340 15 4,0901 3,7574 3,6989.1. Form IV olanzapine polymorph with a typical X-ray powder diffraction pattern represented by the following interplanar distances: 5 d spacing (Å) 9.9487 8.5074 8.2103 10 4.8172 4.7114 4.6122 4.5282 4.2340 15 4, 0901 3.7574 3.6989.
2. Form IV olanzapinpolymorf ifølge krav 1, 20 yderligere karakteriseret ved i det væsentlige følgende røntgenpulverdiffraktionsmønster, hvor d betegner den interplanare afstand, og I/li betegner de typiske relative intensiteter:The Form IV olanzapine polymorph of claim 1, 20 further characterized by substantially the following X-ray powder diffraction pattern, where d represents the interplanar distance and I / l represents the typical relative intensities:
DK 2003 00222 WDK 2003 00222 W
d-afstand (A)_I/Ii 9,9487 83 8,5074 15 8,2103 17 4,8172 100 4,7114 41 4,6122 35 4,5282 33 4,2340 29 4,0901 32 3,7574 23 3,6989 40 .d distance (A) _I / Ii 9.9487 83 8.5074 15 8.2103 17 4.8172 100 4.7114 41 4.6122 35 4.5282 33 4.2340 29 4.0901 32 3.7574 23 3 , 6989 40.
3. Form IV olanzapinpolymorf ifølge krav 1 eller 2, yderligere karakteriseret ved at have et infrarødt spektrum med absorbanser ved følgende bølgetal: 604 661 758 904 931 1365 1456 .Form IV olanzapine polymorph according to claim 1 or 2, further characterized by having an infrared spectrum of absorbances at the following wave numbers: 604 661 758 904 931 1365 1456.
4. Form IV olanzapinpolymorf ifølge krav 1, 2 eller 3 fremstillet ved følgende fremgangsmåde: opløsning af Form I eller Form II olanzapin i ca. 38% vandig myresyre, og præcipitering af i det væsentlige ren Form IV olanzapin under anvendelse af ca. 10% methanolisk natriumhydroxid, hvor Form I olanzapin er en olanzapinpolymorf med et typisk røntgenpulverdiffraktionsmønster repræsenteret ved følgende interplanare afstande:The Form IV olanzapine polymorph according to claim 1, 2 or 3 prepared by the following method: dissolving Form I or Form II olanzapine in ca. 38% aqueous formic acid, and precipitation of substantially pure Form IV olanzapine using approx. 10% methanolic sodium hydroxide, wherein Form I olanzapine is an olanzapine polymorph with a typical X-ray powder diffraction pattern represented at the following interplanar distances:
DK 2003 00222 WDK 2003 00222 W
d-afstande (Å) 9,9463 8,5579 8,2445 5 6,8862 6,3787 6,2439 5,5895 5,3055 10 4,9815 4,8333 4,7255 4,6286 4,553 15 4,4624 4,2915 4,2346 4,0855 3,8254 20 3,7489 3,6983 3,5817 3,5064 3,3392 25 3,2806 3,2138 3,1118 3,0507 2,948 30 2,8172 2,7589 2,6597d-distances (Å) 9.9463 8.5579 8.2445 5.8.8862 6.3787 6.2439 5.5895 5.3055 10 4.9815 4.8333 4.7255 4.6286 4.553 15 4.4624 4 , 2915 4,2346 4,0855 3,8254 3,7489 3,6983 3,5817 3,5064 3,3392 25 3,2806 3,2138 3,1118 3,0507 2,948 30 2,8172 2,7589 2, 6597
DK 2003 00222 WDK 2003 00222 W
d-afstande (Å) 2,6336 2,5956; 5 og Form II olanzapin er en olanzapinpolymorf med et typisk røntgendiffraktionsmønster repræsenteret ved føgende interplanare afstande: d-afstande (Å) 10,2689 10 8,577 7,4721 7,125 6,1459 6,071 15 5,4849 5,2181 5,1251 4,9874 4,7665 20 4,7158 4,4787 4,3307 4,2294 4,141 25 3,9873 3,7206 3,5645 3,5366 3,3828 30 3,2516 3,134 3,0848 3,0638d-distances (Å) 2.6336 2.5956; 5 and Form II olanzapine is an olanzapine polymorph with a typical X-ray diffraction pattern represented by the following interplanar distances: d-distances (Å) 10,2689 10 4,7665 20 4,7158 4,4787 4,3307 4,2294 4,141 25 3,9873 3,7206 3,5645 3,5366 3,3828 30 3,2516 3,134 3,0848 3,0638
DK 2003 00222 WDK 2003 00222 W
d-afstande (Å) 3,0111 2,8739 2,8102 2,7217 2,6432 2,6007.d-distances (Å) 3.0111 2.8739 2.8102 2.7217 2.6432 2.6007.
5. Form IV olanzapinpolymorf ifølge krav 1, 2 eller 3 fremstillet ved følgende fremgangsmåde: opløsning af Form I eller Form II olanzapin i ca. 43% vandig eddikesyre, og præcipitering af i det væsentlige ren Form IV olanzapin under anvendelse af ca. 25% vandig ammoniak, hvor Form I olanzapin er en olanzapinpolymorf med et typisk røntgenpulverdiffraktionsmønster repræsenteret ved følgende interplanare afstande: d-afstande (Å) 9,9463 8,5579 8,2445 6,8862 6,3787 6,2439 5,5895 5,3055 4,9815 4,8333 4,7255 4,6286 4,533 4,4624The Form IV olanzapine polymorph according to claim 1, 2 or 3 prepared by the following method: dissolving Form I or Form II olanzapine in ca. 43% aqueous acetic acid, and precipitation of substantially pure Form IV olanzapine using approx. 25% aqueous ammonia, wherein Form I olanzapine is an olanzapine polymorph with a typical X-ray powder diffraction pattern represented by the following interplanar distances: d-distances (Å) 9.9463 8.5579 8.2445 6.8862 6.3787 6.2439 5.5895 5 , 3055 4.9815 4.8333 4.7255 4.6286 4.533 4.4624
DK 2003 00222 WDK 2003 00222 W
d-afstande (Å) 4,2915 4,2346 4,0855 5 3,8254 3,7489 3,6983 3,5817 3,5064 10 3,3392 3,2806 3,2138 3,1118 3,0507 15 2,948 2,8172 2,7589 2,6597 2,6336 20 2,5956; og Form II olanzapin er en olanzapinpolyamorf med et typisk røntgenpulverdiffraktionsmønster repræsenteret ved følgende interplanare afstande: d-afstande (Å) 25 10,2698 8,577 7,4721 7,125 6,1459 30 6,071 5,4849 5,2181 5,1251d-distances (Å) 4.2915 4.2346 4.0855 5 3.8254 3.7489 3.6983 3.5817 3.5064 10 3.3392 3.2806 3.2138 3.11118 3.0507 2.948 2 , 8172 2.7589 2.6597 2.6336 2.5956; and Form II olanzapine is an olanzapine polyamorph with a typical X-ray powder diffraction pattern represented by the following interplanar distances: d-distances (Å) 25
DK 2003 00222 WDK 2003 00222 W
d-afstande (Å) 4,9874 4,7665 4,7158 4,4787 4,3307 4,2294 4,141 3,9873 3,7206 3,5645 3,5366 3,3828 3,2516 3,134 3,0848 3,0638 3,0111 2,8739 2,8102 2,7217 2,6432 2,6007.d-distances (Å) 4,9874 4,7665 4,7158 4,4787 4,3307 4,2294 4,141 3,9873 3,7206 3,5645 3,5366 3,3828 3,2516 3,134 3,0848 3,0638 3,0111 2.8739 2.8102 2.7217 2.6432 2.6007.
6. Farmaceutisk formulering, der som aktiv ingrediens indeholder mindst en olanzapinpolymorf i forbindelse med en eller flere farmaceutisk acceptable bærere, excipienser eller diluenter derfor, hvor nævnte mindst ene olanzapinpolymorf er udvalgt fra gruppen bestående af Form IV olanzapin og salte og blandinger deraf, og hvor Form IV olanzapin er en olanzapinpolymorf med et typisk røntgenpulverdiffraktionsmønster repræsenteret ved følgende interpla-nare afstande:A pharmaceutical formulation containing as an active ingredient at least one olanzapine polymorph in association with one or more pharmaceutically acceptable carriers, excipients or diluents thereof, wherein said at least one olanzapine polymorph is selected from the group consisting of Form IV olanzapine and salts and mixtures thereof, and wherein Form IV olanzapine is an olanzapine polymorph with a typical X-ray powder diffraction pattern represented at the following interplanar distances:
DK 2003 00222 WDK 2003 00222 W
7. Anvendelse af mindst en olanzapinpolymorf til fremstilling af et lægemiddel til behandling af en 5 tilstand udvalgt fra gruppen bestående af en psykotisk tilstand, mild angst og gastrointestinale tilstande, hvor nævnte mindst ene olanzapinpolymorf er udvalgt fra gruppen bestående af Form IV olanzapin og salte og blandinger deraf, og hvor Form IV olan-10 zapin er en olanzapinpolymorf med et typisk røntgenpulverdiffraktionsmønster repræsenteret ved følgende interplanare afstande:Use of at least one olanzapine polymorph for the manufacture of a medicament for the treatment of a condition selected from the group consisting of a psychotic state, mild anxiety and gastrointestinal conditions wherein said at least one olanzapine polymorph is selected from the group consisting of Form IV olanzapine and salts and mixtures thereof, and wherein Form IV olan-zapine is an olanzapine polymorph with a typical X-ray powder diffraction pattern represented at the following interplanar distances:
DK 2003 00222 WDK 2003 00222 W
DK 2003 00222 WDK 2003 00222 W
hO'OZhO'OZ
coIIcoli
~ i ~ i I 1 i 1 1 1 I 1 1 l i 1 i 1 l i—ΓΓ o o o o o o o o o o CO uo %T CO C\J~ i ~ i I 1 i 1 1 1 I 1 1 l i 1 i 1 l i — ΓΓ o o o o o o o o o CO uo% T CO C \ J
4000.0 3000.0 2000.0 1500.0 1000.0 500.0 — OLANZAPIN - FORM III (KBr) FT - IR SPEKTRUM 1/Cm4000.0 3000.0 2000.0 1500.0 1000.0 500.0 - OLANZAPINE - FORM III (KBr) FT - IR SPECTRUM 1 / Cm
DK 2003 00222 WDK 2003 00222 W
OLANZAPIN - FORM IV (KBr) FT-IR SPEKTRUM 1/Cm d) LlOLANZAPINE - FORM IV (KBr) FT-IR SPECTRUM 1 / Cm d) Ll
DK 2003 00222 WDK 2003 00222 W
4000.0 3000.0 2000.0 1500.0 1000.0 500.0 — OLANZAPIN - FORM V (KBr) FT-IR SPEKTRUM 1/cm4000.0 3000.0 2000.0 1500.0 1000.0 500.0 - OLANZAPIN - FORM V (KBr) FT-IR SPECTRUM 1 / cm
80.CH80.CH
COCO
d) li-d) li-
DK 2003 00222 WDK 2003 00222 W
Shimadzu XRD-6000 CuKa (1,54060 A) 30 kV, 30mA Spalter: DS 1,00 gr, SS:1,00gr„ RS: 0,15 mm Theta-2Theta (gr.) Firma: X-RAY DIFFRACTION 5000-]-1Shimadzu XRD-6000 CuKa (1.54060 A) 30 kV, 30mA Columns: DS 1.00 gr, SS: 1.00 gr „RS: 0.15 mm Theta-2Theta (gr.) Company: X-RAY DIFFRACTION 5000- ] -1
Therta-2Theta (gr.) Kont.Scan. 2,0 gr./min 0,60 sek 0,020 gr. RØNTGENDIFFRAKTIONSMØNSTER - FORM IIITherta-2Theta (gr.) Cont.Scan. 2.0 gr / min 0.60 sec 0.020 gr X-ray diffraction pattern - FORM III
Shimadzu XRD-6000 CuKa (1,54060 A) 30 kV, 30mA Spalter: DS 1,00 gr, SS:1,00 gr„ RS: 0,15 mm Theta-2Theta (gr.J 1 Firma: X-RAY DIFFRACTION :Shimadzu XRD-6000 CuKa (1.54060 A) 30 kV, 30mA Columns: DS 1.00 gr, SS: 1.00 gr „RS: 0.15 mm Theta-2Theta (gr.J 1 Company: X-RAY DIFFRACTION :
CD O O ω V) o to o' O 1 CN Od Li-CD O O ω V) o to o 'O 1 CN Od Li-
DK 2003 00222 WDK 2003 00222 W
od ood o
LLLL
LU I— COLU I— CO
z s sz s s
COCO
i g ΐ *i g ΐ *
Di < 0 Od CN t 1 gTue <0 Od CN t 1 g
o ^ CO UJo ^ CO UJ
- o O £ ^ Si a:- o O £ ^ Si a:
DK 2003 00222 WDK 2003 00222 W
Shimadzu XRD-6000 CuKa (1,54060 A) 30 kV, 30mA Spalter: DS 1,00 ar. SS:1,00 gr,, RS: 0,15 mm Theta-2Theta (gr.) Firma: X-RAY DIFFRACTIONShimadzu XRD-6000 CuKa (1.54060 A) 30 kV, 30mA Column: DS 1.00 ar. SS: 1.00 gr ,, RS: 0.15 mm Theta-2Theta (gr.) Company: X-RAY DIFFRACTION
Therta-2Theta (gr.) Kont.Scan. 2,0 gr./min 0,60 sek 0,020 gr. RØNTGENDIFFRAKTIONSMØNSTER - FORM V w (SdO) ITherta-2Theta (gr.) Cont.Scan. 2.0 gr / min 0.60 sec 0.020 gr X-ray diffraction pattern - FORM V w (SdO) I
CDQ) LLCDQ) LL
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN977BO1999 IN187439B (en) | 2000-03-31 | 1999-12-28 | |
| US09/540,749 US6348458B1 (en) | 1999-12-28 | 2000-03-31 | Polymorphic forms of olanzapine |
| DK200300161U DK200300161U3 (en) | 1999-12-28 | 2003-06-16 | New polymorphic form of olanzapine, designated Form III |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DK200300222U1 DK200300222U1 (en) | 2003-08-25 |
| DK200300222U3 true DK200300222U3 (en) | 2003-12-12 |
Family
ID=28794650
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200300221U DK200300221U3 (en) | 1999-12-28 | 2003-08-25 | New polymorphic form of olanzapine designated Form V. |
| DK200300222U DK200300222U3 (en) | 1999-12-28 | 2003-08-25 | New polymorphic form of olanzapine designated Form IV. |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK200300221U DK200300221U3 (en) | 1999-12-28 | 2003-08-25 | New polymorphic form of olanzapine designated Form V. |
Country Status (1)
| Country | Link |
|---|---|
| DK (2) | DK200300221U3 (en) |
-
2003
- 2003-08-25 DK DK200300221U patent/DK200300221U3/en active
- 2003-08-25 DK DK200300222U patent/DK200300222U3/en active
Also Published As
| Publication number | Publication date |
|---|---|
| DK200300222U1 (en) | 2003-08-25 |
| DK200300221U3 (en) | 2003-12-12 |
| DK200300221U1 (en) | 2003-08-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA97004127A (en) | Benzimidazole derivatives with antihistaminic activity. | |
| EP2253309A3 (en) | Gastric acid secretion inhibiting composition | |
| ES2204354T1 (en) | TORSEMIDA POLYMORPHES. | |
| RU2000122435A (en) | INDOL DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS INCLUDING THEM | |
| JP2003527319A5 (en) | ||
| CN1210025C (en) | Tanshinone compound containing dihydrofuran ring structure for curing hyperammonemia and hepatic encephalopathy | |
| DK200300222U3 (en) | New polymorphic form of olanzapine designated Form IV. | |
| DK200300161U3 (en) | New polymorphic form of olanzapine, designated Form III | |
| GB1578542A (en) | Thienopyridines | |
| ES2309340T3 (en) | K CHANNEL OPENER ACTIVATED BY HIGH CONDUCTANCE CALCIUM. | |
| JP6785792B2 (en) | Highly water-soluble salts of short-acting phenylalkylamine calcium channel blockers and their use | |
| NZ568412A (en) | S-omeprazole strontium or hydrate thereof, method for preparing same, and pharmaceutical composition comprising same. | |
| CA2570795A1 (en) | Process for the preparation of crystal modifications for use in the preparation of esomeprazole sodium salt | |
| CN100364989C (en) | Prazole derivative and its salt and use | |
| JP5017274B2 (en) | S-omeprazole strontium salt or hydrate thereof, process for producing the same, and pharmaceutical composition containing the same | |
| EP2040697A2 (en) | Polymorphic form of duloxetine hydrochloride | |
| JP2524420B2 (en) | Piperidine derivatives and antiulcer agents containing them as active ingredients | |
| JPH0434967B2 (en) | ||
| WO2004032854A3 (en) | Pharmaceutical compositions for treatment of parkinson's disease | |
| US4172145A (en) | Benzo(b)furylacetic acid derivatives to reduce inflammation | |
| AU2003272099B2 (en) | Large conductance calcium-activated K channel opener | |
| JPH01121289A (en) | Pyrolo(1, 2-b)cynnoline and its production | |
| US20100324078A1 (en) | Crystalline Forms of Naltrexone Methobromide | |
| EP1478622A1 (en) | Crystalline anhydrous and monohydrate benzoate salts of (2's,3s)-3-hydroxy-n- 2 n-methyl-n-4-(n-propylamino-carbonyl)phenyl]amino-2-phenyl -ethylpyrrolidine | |
| CN105732612A (en) | Preparation and medical application of ACEI (angiotensin converting enzynme inhibitor)-type berberine conjugate |